A comprehensive 2026 study of the Mexican population has identified 32 genetic variants across 17 different genes that significantly influence Parkinson’s disease risk, marking a major shift toward understanding how this neurodegenerative disorder manifests across diverse genetic backgrounds. Researchers established the Mexican Parkinson’s Research Network (MEX-PD) in 2021, analyzing whole-genome data from 530 control participants and 470 Parkinson’s patients to map these genetic signatures. This work challenges the assumption that genetic risk factors identified in European and Asian populations tell the complete story—a 65-year-old woman from Mexico City with a family history of tremor, for instance, may carry risk variants that researchers had never specifically documented in her population before this study.
The research prioritized four genes for immediate investigation: NOTCH, LRRK2, MTHFR, and KPNA1, each playing distinct roles in neuronal health and protein processing. Rather than claiming a single genetic cause, the findings reveal a complex landscape where multiple variants combine to influence disease susceptibility, age of onset, and symptom severity. This precision matters because it opens pathways for targeted screening and treatment strategies tailored to populations that have historically been underrepresented in neuroscience research.
Table of Contents
- Which Genetic Variants Define Parkinson’s Risk in Mexican Populations?
- The Mexican Parkinson’s Research Network: How a Systematic Approach Revealed Hidden Genetic Architecture
- SNCA Variants and High-Risk Haplotypes: Understanding Sporadic Parkinson’s at the Molecular Level
- Age of Diagnosis and Early-Onset Parkinson’s: Genetic Insights from the Mexican Cohort
- Cytokine Genetics and Inflammation: New Evidence from 2025 Research
- Comparing Genetic Findings: How Mexican PD Genetics Differ from and Mirror Other Populations
- From Genetic Discovery to Clinical Application: What Comes Next for Parkinson’s Care
- Frequently Asked Questions
Which Genetic Variants Define Parkinson’s Risk in Mexican Populations?
The 32 identified variants span mechanisms critical to neuronal survival and mitochondrial function. Some affect protein synthesis, others regulate inflammation, and still others influence cellular waste disposal—processes that break down in Parkinson’s disease.
The MEX-PD cohort’s size and ethnic specificity mean these variants carry relevance for approximately 130 million people in Mexico and similar populations in Central America and the southwestern United States, communities where previous genetic research had been sparse. Four genes emerged as particularly significant: NOTCH regulates neuronal development and survival; LRRK2 (leucine-rich repeat kinase 2) is already implicated in familial Parkinson’s and now shows new sporadic disease associations in Mexican patients; MTHFR handles folate metabolism, which connects to both genetic risk and potentially modifiable environmental factors; and KPNA1 manages nuclear transport of proteins, a pathway disrupted in neurodegeneration. The distinction matters clinically: a patient carrying variants in LRRK2, for example, might be monitored differently than someone with MTHFR variants, because LRRK2 inhibitors are already in clinical development while MTHFR-linked disease might respond to nutritional interventions like high-dose folate supplementation.
The Mexican Parkinson’s Research Network: How a Systematic Approach Revealed Hidden Genetic Architecture
The MEX-PD cohort established in 2021 represents one of the first large-scale, population-specific genetic investigations of Parkinson’s in Mexico. With 470 diagnosed PD patients matched against 530 healthy controls, researchers applied whole-genome genotyping rather than candidate-gene studies, meaning they cast a wide net across the entire genetic code rather than testing only suspected culprits. This approach is more expensive and computationally intensive but avoids the blind spot of hypothesis-driven research—finding variants no one thought to look for.
The systematic review synthesized findings across multiple studies to identify these 32 variants with high confidence. One limitation of this approach: some variants were identified in smaller subsets of patients, meaning their true disease relevance requires validation in independent cohorts. The research also acknowledges that genetic findings in one population don’t automatically apply elsewhere; a variant protective in northern Europeans might carry different risk in Mexican individuals due to other genetic or environmental interactions. Future work will need to replicate these findings and test whether the prioritized genes (NOTCH, LRRK2, MTHFR, KPNA1) actually predict disease course or drug response in prospective studies.
SNCA Variants and High-Risk Haplotypes: Understanding Sporadic Parkinson’s at the Molecular Level
Four specific variants in the SNCA gene—rs356220, rs356203, rs7684318, and rs2736990—combine to form two high-risk haplotypes (inherited variant patterns) associated with sporadic Parkinson’s in the Mexican population. SNCA encodes alpha-synuclein, the protein that misfolds and aggregates in Parkinson’s pathology, choking neuronal function. A 58-year-old man from Guadalajara carrying one of these haplotypes may face a notably higher statistical risk of developing motor symptoms like bradykinesia (slow movement) or rigidity compared to someone without these variants, though inheritance of the haplotype does not guarantee disease will manifest.
The haplotype concept is critical because it reflects biological reality: these four variants don’t act independently but travel together on the same chromosome, co-inherited as a unit. This means testing a single variant misses predictive power, but testing all four together reveals risk more accurately. The research distinguishes these from rare familial mutations; these haplotypes contribute to common, sporadic PD, affecting thousands of Mexicans without a known family history. One practical warning: genetic testing for these variants is not yet standard clinical care in most settings, and interpreting them requires informed consent about what positive results do and do not predict.
Age of Diagnosis and Early-Onset Parkinson’s: Genetic Insights from the Mexican Cohort
The MEX-PD study reported a mean age of Parkinson’s diagnosis of 59.9 ± 11.52 years, with 21.2% of the patient cohort identified as having early-onset Parkinson’s disease (typically defined as symptom onset before age 50). This distribution hints that specific genetic variants may associate with earlier disease emergence, though the study identifies the pattern without yet pinpointing exactly which variants drive the early-onset group. A 42-year-old woman with tremor onset, for instance, might carry genetic combinations distinct from a 72-year-old man whose first symptoms appeared at 70.
Early-onset patients often face different diagnostic challenges and disease trajectories than typical-onset patients. They’re more likely to have atypical initial symptoms, experience higher rates of cognitive preservation in early stages (potentially masking disease from healthcare providers), and face longer disease duration before end-stage disability. The finding that one-fifth of the MEX-PD patient cohort had early onset underscores that genetic risk does not distribute evenly across age groups. Comparing to European cohorts, which report early-onset rates of 15-20%, the Mexican prevalence appears similar, suggesting that early-onset susceptibility variants are shared across populations despite the population-specific findings overall.
Cytokine Genetics and Inflammation: New Evidence from 2025 Research
A 2025 study, building on the MEX-PD framework, examined genetic variants in three cytokines—IL-10, IL-17A, and IL-13—in 239 sporadic PD patients and 84 healthy controls, all Mexican. The study identified specific variants associated not only with disease presence but also with symptom severity, suggesting that inflammatory genetic architecture influences how aggressive Parkinson’s becomes in individual patients. IL-10 is an anti-inflammatory cytokine; variants that reduce its production might leave the brain more vulnerable to neuroinflammation. IL-17A and IL-13 drive pro-inflammatory responses, and carrying variants that amplify their activity could worsen neurodegeneration.
One limitation of cytokine genetic studies: they measure genetic predisposition to inflammation, not inflammation itself. A person carrying a “high IL-17A” variant may never develop high IL-17A levels if environmental triggers (infection, stress, diet) don’t activate the pathway. Conversely, some Parkinson’s patients with severe inflammation may not carry the “risk” variants, pointing to other inflammatory mechanisms at play. The research also used a relatively modest control group size (84), which limits statistical power to detect protective variants or variants with small effect sizes. This work opens the door to testing whether anti-inflammatory drugs (like existing TNF-alpha inhibitors or experimental IL-17A blockers) might slow disease in Mexican PD patients carrying specific cytokine variants, though no clinical trials of this hypothesis have launched yet.
Comparing Genetic Findings: How Mexican PD Genetics Differ from and Mirror Other Populations
The 32 variants identified in the Mexican population overlap partially with those found in European and East Asian cohorts, but the frequency and effect sizes differ. LRRK2, for example, is a major Parkinson’s gene worldwide, but specific variants within LRRK2 show different prevalence in Mexican versus Ashkenazi Jewish or Asian populations. NOTCH and KPNA1 emerged as priorities in the Mexican study but receive less emphasis in non-Hispanic cohorts, suggesting genuine population-specific genetic architecture.
This distinction has practical implications: a genetic test optimized for European populations may miss relevant variants in Mexican patients, leading to false reassurance. The MEX-PD study illustrates why disease research must include diverse populations rather than assuming findings from one ethnic group generalize universally. Diseases like Parkinson’s, once studied almost exclusively in European cohorts, showed gaps in clinical trial data, biomarker understanding, and genetic discovery that disadvantaged non-European patients seeking precision medicine. The Mexican research begins to close that gap, though it also raises a resource challenge: most Parkinson’s genetic research funding flows to wealthy nations, so studies like MEX-PD depend on international collaboration and regional grant support that isn’t always sustained.
From Genetic Discovery to Clinical Application: What Comes Next for Parkinson’s Care
Identifying 32 genetic variants and prioritizing four genes represents foundational science, not immediate clinical magic. The next steps involve functional studies—determining exactly how MTHFR variants alter folate metabolism, or how NOTCH variants affect neuronal survival—followed by prospective studies that test whether these variants predict drug response, disease progression rate, or biomarker elevation. Clinical trials targeting LRRK2 are already underway globally; variants in this gene found in Mexican patients will inform whether existing LRRK2 inhibitors (like those in Phase 2 development) work equally well across populations, or whether genetic differences demand drug modifications.
The MEX-PD cohort and its findings create an infrastructure for future work: researchers now have baseline genetic data on 470 Mexican PD patients and can follow them prospectively to see which genetic profiles associate with motor decline, cognitive decline, or medication response. One practical example: if MTHFR variants show strong association with symptom severity in this cohort, clinicians might routinely screen new Mexican PD patients for MTHFR status and recommend targeted B-vitamin supplementation as adjunctive therapy, similar to how some neurologists already counsel folate in other conditions. The research also identifies patients who might benefit from experimental therapies targeting specific pathways; a 56-year-old man with both LRRK2 and SNCA haplotype variants, for instance, becomes a candidate for LRRK2 inhibitor trials if they enroll Mexican sites.
Frequently Asked Questions
Does carrying one of these 32 genetic variants mean I will definitely develop Parkinson’s disease?
No. These are risk variants, meaning they increase statistical susceptibility, not guarantee disease. Many people carry these variants without ever developing Parkinson’s, while some people without these variants do develop the disease, suggesting environmental triggers, other genes, and chance all play roles.
Are genetic tests for these variants available to patients in Mexico right now?
Not as standard clinical screening. The MEX-PD research is primarily academic; clinical genetic testing for Parkinson’s in Mexico remains limited compared to the United States or Europe. Patients interested in genetic testing should ask their neurologist whether it’s available at their healthcare center or through research programs.
If I have Mexican ancestry but live outside Mexico, do these findings apply to me?
Likely partially. Genetic variants identified in Mexican-descent individuals often show similar frequencies in Mexican-American populations in the southwestern United States, but other ancestry contributions in admixed individuals may modify risk. Ancestry-matched research is always more precise than cross-population extrapolation.
What is a haplotype, and why does it matter for SNCA?
A haplotype is a group of genetic variants that are inherited together on the same chromosome. The four SNCA variants (rs356220, rs356203, rs7684318, rs2736990) form two distinct haplotypes; testing all four together predicts risk better than testing any single variant alone, because they act as a unit.
How soon will this research lead to new Parkinson’s treatments?
Genetic discovery is a long pipeline. Understanding these variants may inform drug development over the next 5-10 years, but clinical trials take years more. Some existing drugs targeting LRRK2 and neuroinflammation may be tested in Mexican patients with relevant variants sooner than wholly new treatments.